


Supplementary Fig. 6. Subgroup analyses by response to prior triptan therapy (good or insufficient) for headache pain-freedom, MBS-freedom, headache pain relief, disability freedom, and PGIC rating of very much/much better 2 hours post-first dose with lasmiditan versus placebo in the triptan 2+ user subpopulation (lasmiditan doses combined due to small patient numbers)



*P<0.05 vs. placebo; **P<0.01 vs. placebo, ***P<0.001 vs. placebo
†Assessed in the modified intention-to-treat (ITT) population
††Assessed in the ITT population
MBS, most bothersome symptom; PGIC, Patient Global Impression of Change